SARS-CoV-2 variants remodel cellular landscapes
Viruses are obligate intracellular parasites, which means they rely on the cellular machinery within their hosts to replicate and assemble new virus particles. To achieve this, they have evolved sophisticated ways to hijack and alter cells while simultaneously overcoming an arsenal of immune defenses activated by viral infection.
Christian Münch, Sandra Ciesek and a team of scientists at Goethe University in Germany study how viruses can rewire their host cells. “We are keen on understanding cellular signaling responses to stress stimuli, such as viral infection,” Münch said.
Coronaviruses are a genus that infects many species, especially mammals and birds. Experts believe severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2, crossed the species barrier and entered the human population to cause the COVID-19 pandemic. Since its detection in Wuhan, China, SARS-CoV-2 has mutated numerous times, resulting in the emergence of multiple variants. These variants may behave distinctly from one another, which can lead to reduced efficacy of antiviral treatments in patients.
The appearance of SARS-CoV-2 variants “definitely tickled our curiosity to examine host cellular antiviral responses,” Münch said. The team’s of these variants was published in the journal ͵͵ & Cellular Proteomics.
Led by Melinda Metzler and Rebecca Tharyan, the researchers began this investigation by infecting cells from lung tissue, the primary target of the virus in humans. They inoculated these lung cells with three viruses: the ancestral SARS-CoV-2 strain, the delta variant, and the omicron variant. The team discovered that the omicron variant replicated remarkably slower within these lung cells than the delta variant or ancestral strain. This was the first experimental indication of a unique cellular response to omicron infection.
Inside every cell are millions of proteins collectively known as the proteome. The scientists next sought to uncover what changes occurred in the proteomes of both the lung cell and the virus during infection.
“To study these time-resolved processes, we developed novel proteomics methods and set up a platform for cellular proteome profiles upon infection,” Tharyan said.
The researchers extracted the proteins from samples and then used mass spectrometry to identify and measure differences in protein quantities among cells infected with the three SARS-CoV-2 strains.
The proteomic analyses showed major cellular changes in all three infected samples, but cells infected by the omicron variant consistently exhibited alterations absent from the other strains. They detected the viral proteome to be significantly reduced in omicron-infected cells as well. Of particular interest was that the researchers also saw striking immunological delays in how cells responded to omicron.
Interferon, or IFN, proteins are a first line of defense against viruses. Omicron-infected cells took much longer to induce IFN proteins than the ancestral SARS-CoV-2 strain or delta variant, suggesting that the omicron virus was able to impede immune activation in these lung cells.
“It was intriguing to unravel such individuality in cellular responses at both proteome and molecular level,” Tharyan said.
Medical records indicate that compared to other variants, omicron infection results in milder cases of COVID-19. Despite its diminished disease burden, the omicron variant is significantly more contagious. Considering these facts, along with their findings on the lagging immune response to this particular variant, Tharyan and her colleagues concluded that in the case of omicron, “slow and steady wins the race.”
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition weekly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles
Guiding grocery carts to shape healthy habits
Robert “Nate” Helsley will receive the Walter A. Shaw Young Investigator in Lipid Research Award at the 2025 ASBMB Annual Meeting, April 12–15 in Chicago.
Quantifying how proteins in microbe and host interact
“To develop better vaccines, we need new methods and a better understanding of the antibody responses that develop in immune individuals,” author Johan Malmström said.
Leading the charge for gender equity
Nicole Woitowich will receive the ASBMB Emerging Leadership Award at the 2025 ASBMB Annual meeting, April 12–15 in Chicago.
CRISPR gene editing: Moving closer to home
With the first medical therapy approved, there’s a lot going on in the genome editing field, including the discovery of CRISPR-like DNA-snippers called Fanzors in an odd menagerie of eukaryotic critters.
Finding a missing piece for neurodegenerative disease research
Ursula Jakob and a team at the University of Michigan have found that the molecule polyphosphate could be what scientists call the “mystery density” inside fibrils associated with Alzheimer’s, Parkinson’s and related conditions.
From the journals: JLR
Enzymes as a therapeutic target for liver disease. Role of AMPK in chronic liver disease Zebrafish as a model for retinal dysfunction. Read about the recent JLR papers on these topics.